Theravance Biopharma Inc - Asset Resilience Ratio

Latest as of September 2025: 37.29%

Theravance Biopharma Inc (0TB) has an Asset Resilience Ratio of 37.29% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€154.91 Million

≈ $181.10 Million USD Cash + Short-term Investments

Total Assets

€415.46 Million

≈ $485.72 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how Theravance Biopharma Inc's Asset Resilience Ratio has changed over time. Check Theravance Biopharma Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Theravance Biopharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Theravance Biopharma Inc worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€154.91 Million	37.29%
Total Liquid Assets	€154.91 Million	37.29%

Asset Resilience Insights

Very High Liquidity: Theravance Biopharma Inc maintains exceptional liquid asset reserves at 37.29% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Theravance Biopharma Inc Industry Peers by Asset Resilience Ratio

Compare Theravance Biopharma Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Akero Therapeutics Inc NASDAQ:AKRO	Biotechnology	55.87%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Zealand Pharma A/S CO:ZEAL	Biotechnology	63.98%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Immunitybio Inc NASDAQ:IBRX	Biotechnology	38.07%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Annual Asset Resilience Ratio for Theravance Biopharma Inc (2014–2024)

The table below shows the annual Asset Resilience Ratio data for Theravance Biopharma Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	14.27%	€50.55 Million ≈ $59.10 Million	€354.16 Million ≈ $414.05 Million	-2.19pp
2023-12-31	16.46%	€62.88 Million ≈ $73.51 Million	€382.00 Million ≈ $446.60 Million	+11.64pp
2022-12-31	4.83%	€29.31 Million ≈ $34.27 Million	€607.40 Million ≈ $710.11 Million	-17.45pp
2021-12-31	22.28%	€83.51 Million ≈ $97.63 Million	€374.82 Million ≈ $438.20 Million	-22.81pp
2020-12-31	45.08%	€211.47 Million ≈ $247.24 Million	€469.06 Million ≈ $548.38 Million	-9.40pp
2019-12-31	54.49%	€222.77 Million ≈ $260.44 Million	€408.83 Million ≈ $477.96 Million	+31.77pp
2018-12-31	22.71%	€127.25 Million ≈ $148.77 Million	€560.24 Million ≈ $654.97 Million	-36.10pp
2017-12-31	58.81%	€259.59 Million ≈ $303.48 Million	€441.40 Million ≈ $516.04 Million	+34.35pp
2016-12-31	24.46%	€156.39 Million ≈ $182.83 Million	€639.25 Million ≈ $747.36 Million	+4.56pp
2015-12-31	19.90%	€59.73 Million ≈ $69.83 Million	€300.12 Million ≈ $350.87 Million	-29.07pp
2014-12-31	48.97%	€165.40 Million ≈ $193.37 Million	€337.77 Million ≈ $394.89 Million	--

pp = percentage points

About Theravance Biopharma Inc

F:0TB Germany Biotechnology

Market Cap

$853.08 Million

€729.68 Million EUR

Market Cap Rank

#9570 Global

#1198 in Germany

Share Price

€14.40

Change (1 day)

-0.69%

52-Week Range

€9.35 - €17.50

All Time High

€38.30